Ocumension Therapeutics (5DG.F)

0.8250 -0.0400 (-4.62%) At close: 10:30AM CEST

Ocumension Therapeutics

No. 1858 Yinzhongnan Road
Guoxiang Subdistrict Wuzhong District
Suzhou
China

https://www.ocumension.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 444

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Ye Liu	CEO & Executive Director	762.28k	N/A	1972
Dr. Zhaopeng Hu	Chief Development Officer & Executive Director	283.34k	N/A	1974
Mr. Tim Ruan	CFO & Joint Company Secretary	N/A	N/A	1986
Dr. DongHong Chen	Chief Medical Officer	N/A	N/A	1971
Mr. Qinglei Zuo	Chief Commercial Officer	N/A	N/A	1984
Ms. Tingchan Chen	Joint Company Secretary	N/A	N/A	1995

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. The company offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, uveitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. It had various drug assets in its portfolio. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.

Corporate Governance

Ocumension Therapeutics’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.